Skip to content

Zoetis ZTS Other accrued liabilities

Other accrued liabilities at other companies

Idexx Laboratories logo
Idexx LaboratoriesIDXX
Chewy logo
ChewyCHWY
Scilex Holding Company logo
Scilex Holding CompanySCLX

Other financials

Income statement

See full
Revenue$2.3B+2.9%
Gross profit$1.6B+2.6%
Net income$601.0M-0.2%
EPS (diluted)$1.42+6.0%

Balance sheet

See full
Cash & equivalents$1.9B+8.9%
Total debt$10.0B+48.0%
Total equity$3.2B-30.5%
Total assets$15.2B+7.5%

Cash flow

See full
Operating cash flow$401.0M-22.1%
CapEx$110.0M-38.2%
Free cash flow$291.0M-13.6%

Valuation

See full
Market cap$30.13B-54.8%
Enterprise value$38.17B-47.3%
P/E11.4×-14.4×
P/S3.2×-4.0×

Profitability

See full
Gross margin71.8%+0.8pp
Net margin27.8%+0.9pp
FCF margin23.5%0.0pp

Returns & leverage

See full
Return on equity67%+15.8pp
Debt / equity3.1×+1.6×
Current ratio3.2×+1.4×

Where this comes from

Reported directly by Zoetis in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Zoetis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zoetis's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zoetis's other accrued liabilities?
Zoetis (ZTS) reported other accrued liabilities of $751M in Q1 2026.
How has Zoetis's other accrued liabilities changed year-over-year?
Zoetis's other accrued liabilities decreased by 2.7% year-over-year, from $772M to $751M.
What is the long-term trend for Zoetis's other accrued liabilities?
Over 5 years (2020 to 2025), Zoetis's other accrued liabilities has grown at a 8.6% compound annual growth rate (CAGR), from $556M to $841M.